Friday, December 11, 2015

CMS(HK) 🗰 招商证券(香港)

Company Report

China Merchants Securities (HK) Co., Ltd. Hong Kong Equity Research

Summit Ascent (102 HK)

CMS Conference takeaways – ramp-up on track

During our Shenzhen Conference with Summit Ascent this week, management reiterated its positive view on the ramp-up of Tigre de Cristal Casino (grand opening in Nov 11, 2015)

■ After operating for a month, the VIP gaming area was enlarged on robust demand. Meanwhile, mass tables and slots were downsized

Mgmt said ramp-up is on track and expected FY15E EBITDA to turn positive, thanks to low tax and opex environment

Daily traffic in upward trend

Tigre de Cristal now welcomes 400-600 daily visits in weekdays and 600-800 in weekends, implying stable ramp-up after 121 hotel rooms are in operation from early November. Weekend foot traffic was strong due to high rollers' visit arranged by casual junkets (c.130 VIP players last weekend). Hotel rooms were running at full occupancy during weekend at average daily rate of US\$200-400, which is relatively high for a 4-star hotel. Majority of mass players were local residents (50%). For VIP segment, 70% of VIP players were from the PRC, mostly from Northeastern provinces, while the remaining 30% were from South Korea.

Strong VIP business; local mass market still needs time

According to mgmt, the property's performance was broadly in line with its expectation, while 1) demand for VIP was strong but 2) demand from low-end local players were weaker than expected, especially for slots. Therefore, mgmt has recently made adjustment in the mix of gaming facilities: 1) increased VIP tables from 25 to 33, 2) withdrew 5 mass tables to 37, 3) halved number of slots from 650 to 350.

Favorable cost environment

Summit Ascent is currently trading at 8.0x FY16E P/E and 8.7x EV/EBITDA, based on consensus forecasts, 30% discount to its gaming peers in terms of EV/EBITDA multiples. Potential re-rating catalysts: 1) solid demand from North-eastern China continues driving up VIP table yield and hotel occupancy rate, 2) monthly opex (US\$3-4mn) is far lower than Macau which market has not fully realized, and 3) low gaming tax (c.2% of GGR).

Financials

HK\$ mn	FY10	FY11	FY12	FY13	FY14
Revenue	89.0	72.3	9.8	8	22
Net profit	1.4	2.3	(6.0)	-80	-79
Growth (%)	n.a.	n.a.	n.a.	n.a.	n.a.
EPS (HK\$)	0.01	0.01	(0.01)	(0.06)	(0.06)
DPS (HK\$)	-	-	-	-	-
P/E (x)	n.a.	n.a.	n.a.	n.a.	n.a.
EV/EBITDA (x)	n.a.	n.a.	n.a.	n.a.	n.a.
Dividend yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%
ROE (%)	0.6%	6.9%	-20.5%	-12.9%	-7.9%

Source: Company data


Please see penultimate page for additional important disclosures. China Merchants Securities (CMS) is a foreign broker-dealer unregistered in the USA. CMS research is prepared by research analysts who are not registered in the USA. CMS research is distributed in the USA pursuant to Rule 15a-6 of the Securities Exchange Act of 1934 solely by Rosenblatt Securities, an SEC registered and FINRA-member broker-dealer. 1

Angela HAN LEE +852 3189 6634 angelahanlee@cmschina.com.hk Ryan YU +852 3189 6268 ryanyu@cmschina.com.hk

WHAT'S NEW N.A.

NON RATED

Previous	NON RATED
Price	HK\$3.38
12-month Target Price (Potential up/downside)	N.A.
Previous	N.A.



(4.1)

(19.2)

(7.2)

Industry: Macau Gaming	
Hang Seng Index	21705
HSCEI	9450
Key Data	
52-week range (HK\$)	2.88 / 6.00
Market cap (US\$ mn)	648
Avg. daily volume (mn shares)	1.4
BVPS (HK\$)	0.7
Shareholdings Structure	
Ho Lawrence, Yau Lung	28%
Wang John Peter Ben	11%
No. of shrs outstanding (shr)	1,485mn
Others	61%

Related Research

HSI

^{1.} Summit Ascent (102 HK) - Tigre de Cristal opening takeaways (NON RATED) 2015/11/13

CMS(HK) 🗰 招商证券(香港)



The integrated entertainment zone ("IEZ") of the Primorsky Krai in the Russian Far East

Source: Company data, CMS (HK)

Company's projects in the integrated entertainment zone ("IEZ") of the Primorsky Krai

	Tigre de Cristal	Phase 2
Soft opening date Grand opening date	October 8, 2015 November 11, 2015	- 2018
Gross land area Gross floor area	90,455sqm 31,630sqm	154,400sqm TBC
Hotel rooms	121	500 4-star hotel with 300 rooms 5-star hotel with 200 rooms
F&B outlets	7	TBC
VIP gaming tables Mass market tables Slot machines	33 37 371	100 70 500
Project cost	US\$172mn	US\$500mn

Source: Company data, CMS (HK)



Peer valuation table


			Target Price			Mkt Cap	Mkt Cap 52-Wk Price	Avg T/O	FY16E PEG/	P/E (x)		
Company	Ticker	Rating	(Icl crncy)	(Icl crncy)	+/-side	(US\$ mn)	(Icl crncy)	(US\$ mn)	FY16E-18E CAGR (x)	FY14		FY16E
Summit Ascent*	102 HK	NR	n.a.	3.38	n.a.	648	2.88 / 6.00	0.7	1.2	n.a.	56.4	8.0
Peers												
Macau Legend*	1680 HK	NR	n.a.	1.05	n.a.	863	0.92 / 3.42	2.8	4.3	14.0	(65.6)	1,050.0
NagaCorp*	3918 HK	NR	n.a.	4.97	n.a.	1,463	4.33 / 6.48	1.6	0.8	10.8	8.5	9.8
Galaxy	27 HK	BUY	31.80	23.20	37%	12,750	19.02 / 47.65	69.8	1.1	9.5	21.8	15.6
SJM	880 HK	SELL	4.00	5.65	-29%	4,124	5.23 / 13.50	11.1	(0.9)	4.7	10.6	17.0
Wynn Macau	1128 HK	BUY	12.90	9.34	38%	6,261	8.45 / 22.79	18.0	0.6	7.5	27.2	20.1
Sands China	1928 HK	BUY	30.00	26.25	14%	27,331	22.85 / 41.30	70.0	0.9	10.7	18.6	18.0
MGM China	2282 HK	NETRL	11.30	9.83	15%	4,820	8.73 / 20.36	8.0	0.6	6.6	11.2	13.5
Melco Crown	MPEL US	NETRL	21.00	16.05	31%	8,740	12.80 / 28.17	65.2	0.7	14.5	56.9	26.6
Simple Avg									1.0	9.8	11.1	146.3
Mkt Cap Avg									0.8	10.0	22.7	31.7

Company Ticker		EV/EBITDA (x)			Di	vidend Yield	(%)	ROE (%)			ND/E (%)
Company	пскег	FY14	FY15E	FY16E	FY14	FY15E	FY16E	FY14	FY15E	FY16E	FY15E
Summit Ascent*	102 HK	n.a.	31.7	8.7	-	-	-	(9.7)	(1.2)	41.1	NetCash
Peers											
Macau Legend*	1680 HK	8.2	27.2	22.9	-	-	-	7.3	(1.4)	(1.2)	10.1
NagaCorp*	3918 HK	7.3	3.8	3.2	6.5	7.6	6.0	22.2	26.5	21.9	NetCash
Galaxy	27 HK	6.8	11.4	9.4	3.1	2.2	2.2	27.4	11.3	14.3	NetCash
SJM	880 HK	3.0	8.5	12.9	14.9	6.6	4.1	27.2	12.6	7.9	11.7
Wynn Macau	1128 HK	6.7	15.8	12.6	18.7	3.1	3.5	91.5	64.3	67.0	751.6
Sands China	1928 HK	8.7	13.9	14.0	7.6	7.6	7.6	39.6	25.3	28.7	39.8
MGM China	2282 HK	5.3	10.3	12.2	13.6	6.2	5.2	90.0	65.9	49.6	205.7
Melco Crown	MPEL US	9.5	15.2	11.7	2.1	0.5	1.1	14.2	3.5	7.0	76.6
Simple Avg		6.9	13.3	12.4	9.5	4.8	4.3	34.4	23.0	26.3	
Mkt Cap Avg		7.6	13.1	12.4	7.8	4.9	4.8	40.9	25.2	26.4	

Note: * are based on market estimates

Source: Company data, Bloomberg, CMS (HK) estimates

Ownership structure



Source: Company data, CMS (HK)

Investment Ratings

Industry Rating	Definition
OVERWEIGHT	Expect sector to outperform the market over the next 12 months
NEUTRAL	Expect sector to perform in-line with the market over the next 12 months
UNDERWEIGHT	Expect sector to underperform the market over the next 12 months

Company Rating	Definition
BUY	Expect stock to generate 10%+ return over the next 12 months
NEUTRAL	Expect stock to generate +10% to -10% over the next 12 months
SELL	Expect stock to generate loss of 10%+ over the next 12 months

Analyst Disclosure

The analysts primarily responsible for the preparation of all or part of the research report contained herein hereby certify that: (i) the views expressed in this research report accurately reflect the personal views of each such analyst about the subject securities and issuers; and (ii) no part of the analyst's compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed in this research report.

Regulatory Disclosure

Please refer to the important disclosures on our website http://www.newone.com.hk/cmshk/en/disclosure.html.

Disclaimer

This document is prepared by China Merchants Securities (HK) Co., Limited ("CMS HK"). CMS HK is a licensed corporation to carry on Type 1 (dealing in securities), Type 2 (dealing in futures), Type 4 (advising on securities), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities under the Securities and Futures Ordinance (Chapter 571). This document is for information purpose only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer or solicitation of an offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever to buy or sell any security, financial instrument or any investment or other specific product. The securities, instruments or strategies discussed in this document may not be suitable for all investors, and certain investors may not be eligible to participate in some or all of them. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. CMS HK is not registered as a broker-dealer in the United States and its products and services are not available to U.S. persons except as permitted under SEC Rule 15a-6.

The information and opinions, and associated estimates and forecasts, contained herein have been obtained from or are based on sources believed to be reliable. CMS HK, its holding or affiliated companies, or any of its or their directors, officers or employees ("CMS Group") do not represent or warrant, expressly or impliedly, that it is accurate, correct or complete and it should not be relied upon. CMS Group will not accept any responsibility or liability whatsoever for any use of or reliance upon this document or any of the content thereof. The contents and information in this document are only current as of the date of their publication and will be subject to change without prior notice. Past performance is not indicative of future performance. Estimates of future performance are based on assumptions that may not be realized. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Opinions expressed herein may differ or be contrary to those expressed by other business divisions or other members of CMS Group as a result of using different assumptions and/or criteria.

This document has been prepared without regard to the individual financial circumstances and investment objectives of the persons who receive it. Use of any information herein shall be at the sole discretion and risk of the user. Investors are advised to independently evaluate particular investments and strategies, take financial and/or tax advice as to the implications (including tax) of investing in any of the securities or products mentioned in this document, and make their own investment decisions without relying on this publication.

CMS Group may have a long or short position, make markets, act as principal or agent, or engage in transactions in securities of companies referred to in this document and may also perform or seek to perform investment banking services or provide advisory or other services for those companies. This document is for the use of intended recipients only and this document may not be reproduced, distributed or published in whole or in part for any purpose without the prior consent of CMS Group. CMS Group will not be liable for any claims or lawsuits from any third parties arising from the use or distribution of this document. This document is for distribution only under such circumstances as may be permitted by applicable law. This document is not directed at you if CMS Group is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. In particular, this document is only made available to certain US persons to whom CMS Group is permitted to make available according to US securities laws, but cannot otherwise be made available, distributed or transmitted, whether directly or indirectly, into the US or to any US person. This document also cannot be distributed or transmitted, whether directly or indirectly, Republic of China (for the purpose of this document, excluding Hong Kong, Macau and Taiwan).



Important Disclosures for U.S. Persons

This research report was prepared by CMS HK, a company authorized to engage in securities activities in Hong Kong. CMS HK is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution solely to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc, 20 Broad Street 26th Floor, New York NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through RMS HK. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Rosenblatt Securities Inc. or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Rosenblatt Securities Inc, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Rosenblatt Securities Inc. is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Rosenblatt Securities Inc. or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CMS HK nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

CMS HK may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CMS HK.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CMS HK with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of CMS HK and CMS HK accepts no liability whatsoever for the actions of third parties in this respect.

Hong Kong

China Merchants Securities (HK) Co., Ltd. Address: 48/F, One Exchange Square, Central, Hong Kong Tel: +852 3189 6888 Fax: +852 3101 0828